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Purpose: To investigate whether the solute carrier family 1, member 3 (SLC1A3) gene, which encodes the glutamate
aspartate transporter, is associated with normal tension glaucoma (NTG) in Japanese patients.
Methods: Two hundred and ninety-five Japanese patients with NTG and 518 Japanese healthy controls were recruited.
Patients exhibiting comparatively early NTG onset were selected because early onset suggests that genetic factors may
show stronger involvement. We genotyped 5 single-nucleotide polymorphisms (SNPs) in SLC1A3 and assessed the allelic
and genotypic diversity among cases and controls.
Results: There were no statistically significant differences in the frequency of SLC1A3 alleles and genotypes between
cases and controls.
Conclusions: Our study showed no association between SLC1A3 and NTG, suggesting that the SLC1A3 gene may not be
an associated factor in NTG pathogenesis.
Glaucoma  is  characterized  by  the  progressive
degeneration of retinal ganglion cells (RGCs) and optic nerve
axons, together with visual field damage, which is usually
associated with elevated intraocular pressure (IOP). Primary
open angle glaucoma (POAG) is the most common type of
glaucoma. Normal tension glaucoma (NTG) is an important
subset of POAG; while many POAG patients have high IOP
[1], patients with NTG have statistically normal IOP [2-4].
NTG is more prevalent in the Asian population, particularly
in the Japanese population [5-7], and recent studies in the
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Japanese population have reported that 92% of patients with
POAG  had  NTG,  with  an  IOP  of  21  mmHg  or  less  [5].
Glaucoma is generally a multifactorial disorder affected by
several interacting factors, and factors other than IOP are
likely to play a role in the pathogenesis of glaucomatous optic
neuropathy, particularly in patients with NTG [8,9].
Glutamate is the most major excitatory neurotransmitter
in  the  mammalian  retina;  excessive  stimulation  of  the
glutamatergic system has been suggested as a risk factor for
the death of RGCs in glaucoma [10-15], and factors such as
reduced ocular blood flow, ocular vascular dysregulation, and
systemic blood pressure alterations have been investigated
extensively [16-18]. The solute carrier family 1, member 3
(SLC1A3)  gene,  which  is  located  on  chromosome  5p13,
encodes  a  glial-type,  high-affinity  glutamate  aspartate
transporter  (GLAST)  [19].  GLAST  is  tightly  regulated  to
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792remove glutamate from the extracellular fluid in the retina,
and is essential to keep extracellular glutamate concentrations
below the neurotoxic level [15,20,21]. Therefore, it has been
hypothesized  that  GLAST  dysfunction  and  the  resultant
elevation of glutamate levels may underlie or contribute to the
death of RGCs in glaucoma patients.
Based  on  published  results,  we  hypothesized  that
SLC1A3 may play an important role in the development of
NTG. To verify this hypothesis, we performed SNP analysis
of  SLC1A3  and  investigated  the  disease  susceptibility  of
SLC1A3 polymorphisms in NTG patients.
METHODS
Participants: We recruited 295 unrelated Japanese patients
with NTG and 518 unrelated healthy Japanese controls at
Yokohama  City  University,  Yamanashi  University,  Gifu
University,  Kobe  University,  Yamaguchi  University,
Kumamoto  University,  Hokkaido  University,  Tokyo
University,  Niigata  University,  Kanazawa  University,
Hiroshima University, Tajimi Municipal Hospital, and Tokai
University in Japan. The criteria used to diagnose NTG have
been previously described [22]. In detail, the patients were
diagnosed  by  the  following  strict  inclusion  criteria:  the
presence  of  glaucomatous  optic  neuropathy  with
corresponding visual field loss; normal open angle with angle
width of Shaffer grade 2 or higher; absence of IOP greater
than  21  mmHg  on  repeat  measurement  using  Goldmann
applanation  tonometry  without  medication;  and  lack  of
pathological basis for optic nerve change upon neurologic,
rhinologic,  and  general  medical  examination,  including
magnetic  resonance  imaging.  Glaucomatous  optic  nerve
abnormality was diagnosed when the vertical cup/disc ratio of
the optic nerve head was 0.7 or higher, the rim width at the
superior (11 to 1 h) or inferior (5 to 7 h) portion was less than
or equal to 10% of the disc diameter, the difference in the
vertical cup/disc ratio between eyes was 0.2 or greater, or a
nerve fiber layer defect was found. Glaucomatous visual field
loss was defined on a hemifield basis using reliable field data
examined  by  the  Humphrey®  static  visual  field  analyzer
(HFA) C-30-2 program (Carl Zeiss Meditec, Oberkochen,
Germany) according to Anderson and Patella’s criteria [23].
The  hemifield  was  judged  abnormal  when  the  pattern
deviation probability plot showed a cluster of 3 or more non-
edge contiguous points having sensitivity with a probability
of less than 5% in the upper or lower hemifield, and in one of
these points with a probability of less than 1%.
In addition, the following inclusion and exclusion criteria
were used to stringently categorize the patient groups. We
excluded individuals who were diagnosed below the age of 20
years or above the age of 60 years, as well as patients for whom
the refractive error was the spherical equivalent of less than -
8.0 diopters (D). In order to correct for the damaging effects
of aging on the retinal ganglion (i.e. the mean deviation [MD]
measured  by  HFA  C-30-2)  the  selection  criteria  were
modified based on subject age, as follows: (i) no modification
if the patient was diagnosed below the age of 50 years, (ii)
-10.00 dB or worse in at least one eye if the patient was
diagnosed between the ages of 50 and 55 years, (iii) -15.00
dB or worse in at least one eye if the patient was diagnosed
above the age of 55 years. Cases with a comparatively early
onset were selected because early onset suggests stronger
involvement of genetic factors. During diagnosis, patients
whose refraction values had changed due to cataract surgery,
refractive  surgery,  etc.,  were  excluded.  In  cases  where
glaucomatous visual field loss was present in only one eye,
the refraction value and glaucomatous visual field loss of the
affected eye were used. In cases where glaucomatous visual
field loss was present in both eyes, the refraction value and
glaucomatous visual field loss of the more severely affected
eye were used.
Patient age ranged between 20 and 59 years (mean age,
46.4±8.1 years); 48.1% of patients were male and 52.5% were
female. The mean refraction value was –4.05±3.00 diopters
(D), and the mean deviation (MD) observed in the Humphrey
static  visual  field  determination  (Carl  Zeiss  Meditec,
Oberkochen, Germany) was −9.77±8.17 dB. Subjects having
certain  ocular  symptoms  were  excluded  from  the  patient
group. In regard to systemic characteristics, 20 (6.8%) patients
had hypertension and 5 (1.7%) patients had diabetes mellitus;
no patients had collagen vascular diseases, cardiac diseases or
other systemic symptoms.
Controls  were  healthy  volunteers  from  a  geographic
region similar to that for the NTG patients, and the control
population  was  comparable  in  age  and  sex  to  the  NTG
patients.  The  subjects  were  disease-free,  with  no
hypertension, diabetes mellitus, collagen vascular disease, or
other  diseases.  Subjects  with  glaucoma  or  other  ocular
disorders  were  not  included  in  the  healthy  control  group.
Controls had no myopia or mild myopia with refractive errors
of −3.00 D or less. This study was approved by the ethics
committee of each participating institute, and complied with
the guidelines of the Declaration of Helsinki. All study details
were explained to all patients and controls before obtaining
consent for genetic screening.
DNA and SLC1A3 genotyping: The QIAamp DNA Blood
Maxi Kit (Qiagen, Hilden, Germany) was used to collect
peripheral blood lymphocytes and extract genomic DNA from
peripheral  blood  cells.  Procedures  were  performed  under
standardized conditions to prevent variation in DNA quality.
We  evaluated  5  single-nucleotide  polymorphisms
(SNPs): rs13173144, rs1366632, rs1428967, rs930072, and
rs2301066. These SNPs are located within the SLC1A3 gene,
which spans over 81 kb on chromosome 5p13 and is composed
of 10 exons, with minor allele frequencies >5% according to
the National Center for Biotechnology Information dbSNP
(Figure 1). Genotyping of all SNPs was performed by TaqMan
5′ exonuclease assay using primers supplied by ABI (Foster
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the TaqMan Assay for Real-Time PCR (7500 Real-Time PCR
System;  Applied  Biosystems),  and  following  the
manufacturer’s instructions.
Statistical analysis: Hardy–Weinberg equilibrium was tested
for each SNP among controls. Differences in allele frequency
between case and control were assessed by χ2 test and Fisher’s
exact test. The software Haploview 3.32 was used to compute
pairwise  linkage  disequilibrium  (LD)  statistics  [24].
Standardized  disequilibrium  (D’)  was  plotted.  Haplotype
blocks were defined according to the criteria of Gabriel et al.
[25]. All p-values were derived from a 2-sided test, and p-
values less than 0.05 were considered statistically significant.
RESULTS
Five SNPs in SLC1A3 were genotyped. The observed and
expected frequencies of each genotype for the five SNPs in
the case and control participants were in Hardy–Weinberg
equilibrium (data not shown), and the minor allele frequencies
of all SNPs were over 5% in controls (Table 1). Figure 1 shows
the strength of LD for the five SNPs in all 813 participants;
no haplotype block was suggested.
The allele and genotype frequencies of the five SNPs in
cases  and  controls  were  listed  in  Table  1  and  Table  2,
Figure 1. Linkage disequilibrium plot of five SLC1A3 SNPs in 813
study participants. A schematic of SLC1A3 is shown as a black line
with black boxes representing the coding region and white boxes
representing the untranslated region. The locations of the genotyped
SNPs are indicated by the dotted line. The D’ value corresponding
to each SNP pair is expressed as a percentage and shown within the
respective square. Higher D’ values are indicated in brighter red.
respectively.  No  statistically  significant  association  was
observed for any of the SNPs between cases and controls
(p>0.05).
DISCUSSION
Glutamate  transporters  play  a  major  role  in  maintaining
physiologic extracellular glutamate levels [10]. A total of five
glutamate  transporters  (GLAST,  glutamate  transporter  1
[GLT-1], excitatory amino acid carrier 1 [EAAC1], excitatory
amino acid transporter 4 [EAAT4], and excitatory amino acid
transporter 5 [EAAT5]) have been cloned and characterized,
and GLAST (also referred to as EAAT1) and GLT-1 (EAAT2)
are dominant transporter types among these [19]. Previous
studies  have  reported  the  possibility  of  GLAST  being
associated with the pathogenesis of glaucoma. Naskar et al.
[26] showed that glaucomatous eyes have a decreased level
of  GLAST.  In  addition,  Harada  et  al.  [27]  reported  that
GLAST-knockout mice showed progressive RGC loss and
glaucomatous optic nerve degeneration without elevated IOP,
suggesting  that  GLAST  dysfunction  plays  a  role  in  NTG
pathogenesis.
The  aim  of  this  study  was  to  investigate  whether
polymorphisms in SLC1A3, the gene that encodes GLAST,
affect the development of NTG. To this end, we genotyped a
series of common variants located in SLC1A3 using Japanese
patients with NTG. Patients exhibiting comparatively early-
onset NTG were selected for this study because early NTG
onset  suggests  that  genetic  factors  may  show  stronger
involvement. Here we report a lack of association between
SLC1A3 variants and NTG in Japanese patients, suggesting
that the possibility of attributing the pathogenesis of NTG to
SLC1A3 genetic variations is low.
Glaucoma is genetically heterogeneous and many genes
have been reported to be associated with the development of
glaucoma  [18,28].  Therefore,  the  identification  of  disease
susceptibility genes could provide new avenues for research
aimed at clarifying the pathogenesis of glaucoma. Although
the  variants  of  SLC1A3  encoding  GLAST  were  not
significantly associated with NTG in this study, the function
of glutamate transporters still seems to have an important role
in the pathogenesis of glaucoma. The other major glutamate
transporter, GLT-1, has also been suggested to contribute to
glaucoma  pathogenesis.  Martin  et  al.  [15]  demonstrated
significant reductions in both GLAST and GLT-1 levels in the
retina of an experimental rat glaucoma model. Sullivan et al.
[29] found the evoked expression of a GLT-1 splice variant
in  human  glaucoma  and  a  rat  glaucoma  model,  while
glaucomatous rats exhibited no change in GLAST level. More
recently,  Park  et  al.  reported  that  GLT-1  expression  was
significantly  increased  in  cauterized  eyes  throughout  the
entire  experimental  period  while  GLAST  expression
remained stable during the experimental period, and surmised
that GLT-1 may be a prerequisite for the maintenance of
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794glutamate  homeostasis  in  the  retina  during  glaucoma
development [30]. Therefore, genetic association studies of
the SLC1A2 gene, which encodes GLT-1, might be needed to
clarify which transporter is the primary glutamate transporter
related to glaucoma pathogenesis.
Various complex diseases often involve the integration
of multiple genetic and environmental factors, and risk alleles
for such diseases confer small effect sizes (odds ratio <1.5)
[31], suggesting that the sample size in this study may have
limited statistical power to detect risk alleles of glaucoma (a
common  disease  with  small  effect  sizes).  Therefore,  our
further genetic association studies will require larger sample
sizes to produce reliable data.
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